[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605014":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":36,"studyPopulation":19,"armGroups":37,"interventions":53,"overallOfficials":19,"centralContacts":63,"locations":69,"responsibleParty":287,"collaborators":19,"id":289,"slug":290,"hasResults":291,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":19,"eligibilityCriteria":295,"healthyVolunteers":291,"sex":296,"minAge":297,"maxAge":19,"enrollmentInfo":298,"targetDuration":19,"studyType":301,"phases":302,"briefSummary":304,"conditions":305,"keywords":19,"overallStatus":72,"whyStopped":19,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":316},{"fullName":5,"class":6},"Traws Pharma, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":19},[9,13],{"measure":10,"description":11,"timeFrame":12},"Safety based on adverse events incidence","Adverse events incidence will be described using descriptive statistics methods","28 days",{"measure":14,"description":15,"timeFrame":12},"Safety based on adverse events severity","Adverse events severity will be assessed by current version of CTCAE",[17,20,22,25,27],{"measure":18,"description":19,"timeFrame":12},"Efficacy based on Time (days) to sustained recovery of all targeted COVID-19 signs\u002Fsymptoms through Day 28",null,{"measure":21,"description":19,"timeFrame":12},"Efficacy based on Time to sustained recovery of each targeted COVID-19 symptom through Day 28.",{"measure":23,"description":19,"timeFrame":24},"PK characteristics of 83-0060 based on Maximum Plasma Concentration (Cmax)","11 days",{"measure":26,"description":19,"timeFrame":24},"PK characteristics of 83-0060 based on Area under the concentration time curve from 0 to time of last quantifiable concentration (AUClast)",{"measure":28,"description":19,"timeFrame":24},"PK characteristics of 83-0060 based on Time to Cmax ( Tmax)",{"allocation":30,"interventionModel":31,"interventionModelDescription":32,"primaryPurpose":33,"observationalModel":19,"timePerspective":19,"maskingInfo":34},"RANDOMIZED","PARALLEL","Participants will be randomized into 3 study arms (30 participant per arm) to receive study drug and standard of care therapy","TREATMENT",{"masking":35,"maskingDescription":19,"whoMasked":19},"NONE","This is a multicenter, open-label, randomized Phase 2a study to evaluate the safety and efficacy of 83-0060 (Ratutrelvir) and Nirmatrelvir-Ritonavir (Paxlovid) in non-hospitalized symptomatic adult participants with mild to moderate COVID-19.",[38,43,49],{"label":39,"type":40,"description":19,"interventionNames":41},"Ratutrelvir (83-0060) non-randomised","EXPERIMENTAL",[42],"Drug: Ratutrelvir (83-0060) non-randomised",{"label":44,"type":45,"description":46,"interventionNames":47},"Paxlovid","ACTIVE_COMPARATOR","Standard of care",[48],"Drug: Paxlovid",{"label":50,"type":40,"description":19,"interventionNames":51},"Ratutrelvir (83-0060)",[52],"Drug: Ratutrelvir (83-0060)",[54,58,61],{"type":55,"name":39,"description":56,"armGroupLabels":57,"otherNames":19},"DRUG","83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)",[39],{"type":55,"name":44,"description":59,"armGroupLabels":60,"otherNames":19},"Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)",[44],{"type":55,"name":50,"description":56,"armGroupLabels":62,"otherNames":19},[50],[64],{"name":65,"role":66,"phone":67,"phoneExt":19,"email":68},"Ekaterina Dokukina","CONTACT","+38269728309","kdokukina@eilenther.com",[70,89,103,118,134,150,165,180,195,204,221,235,245,260,271],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Novatrial","RECRUITING","Charlestown","New South Wales","2290","Australia","AU",{"type":79,"coordinates":80},"Point",[81,82],151.69318,-32.96828,{"lat":82,"lon":81},[85],{"name":86,"role":66,"phone":87,"phoneExt":19,"email":88},"Eliza Milliken","+61240010376","eliza.milliken@novatrials.com.au",{"facility":90,"status":72,"city":91,"state":74,"zip":92,"country":76,"countryCode":77,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Key Health","Sydney","2000",{"type":79,"coordinates":94},[95,96],151.20732,-33.86785,{"lat":96,"lon":95},[99],{"name":100,"role":66,"phone":101,"phoneExt":19,"email":102},"Aaron Wong","+61473404917","aaron.wong@keyhealth.com.au",{"facility":104,"status":72,"city":105,"state":106,"zip":107,"country":76,"countryCode":77,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Momentum Clinical Research Taringa","Brisbane","Queensland","4068",{"type":79,"coordinates":109},[110,111],153.02809,-27.46794,{"lat":111,"lon":110},[114],{"name":115,"role":66,"phone":116,"phoneExt":19,"email":117},"Paul Griffin, Prof","+61733796619","paul.griffin@momentumclinicalresearch.com.au",{"facility":119,"status":120,"city":121,"state":122,"zip":123,"country":76,"countryCode":77,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Paratus Clinical(Clinical Trials Institute, Torquay)","NOT_YET_RECRUITING","Torquay","Victoria","3228",{"type":79,"coordinates":125},[126,127],144.32638,-38.33085,{"lat":127,"lon":126},[130],{"name":131,"role":66,"phone":132,"phoneExt":19,"email":133},"Yagyadutt Gupta","+61342527023","Heenal.patel@paratusclinical.com",{"facility":135,"status":120,"city":136,"state":137,"zip":138,"country":139,"countryCode":19,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Chonnam National University Hospital","Gwangju","Donggu","61469","South Korea",{"type":79,"coordinates":141},[142,143],126.91556,35.15472,{"lat":143,"lon":142},[146],{"name":147,"role":66,"phone":148,"phoneExt":19,"email":149},"Kyung-Hwa Park","+82622206298","iammedkid@naver.com",{"facility":151,"status":120,"city":152,"state":153,"zip":154,"country":139,"countryCode":19,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"The Catholic University of Korea, Eunpyeong St. Mary's Hospital","Seoul","Eunpyeong-gu","07441",{"type":79,"coordinates":156},[157,158],126.9784,37.566,{"lat":158,"lon":157},[161],{"name":162,"role":66,"phone":163,"phoneExt":19,"email":164},"Sang-haak Lee","+82220303758","mdlee@catholic.ac.kr",{"facility":166,"status":120,"city":167,"state":168,"zip":169,"country":139,"countryCode":19,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Wonju Severance Christian Hospital","Wŏnju","Gangwon-do","26426",{"type":79,"coordinates":171},[172,173],127.94528,37.35139,{"lat":173,"lon":172},[176],{"name":177,"role":66,"phone":178,"phoneExt":19,"email":179},"Young-Keun Kim","+82337411209","amoxj@yonsei.ac.kr",{"facility":181,"status":120,"city":182,"state":183,"zip":184,"country":139,"countryCode":19,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Inha University Hospital","Incheon","Jung-gu","22332",{"type":79,"coordinates":186},[187,188],126.70515,37.45646,{"lat":188,"lon":187},[191],{"name":192,"role":66,"phone":193,"phoneExt":19,"email":194},"Jin-Soo Lee","82328901150","ljinsoo@inha.ac.kr",{"facility":196,"status":120,"city":152,"state":152,"zip":154,"country":139,"countryCode":19,"cosmosGeoPoint":197,"geoPoint":199,"contacts":200},"Hallym University Sacred Heart Hospital Gangnam",{"type":79,"coordinates":198},[157,158],{"lat":158,"lon":157},[201],{"name":202,"role":66,"phone":19,"phoneExt":19,"email":203},"Jacob Lee","litjacob@gmail.com",{"facility":205,"status":120,"city":206,"state":207,"zip":208,"country":209,"countryCode":210,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Kaohsiung Medical University Hospital","Kaohsiung City","Kaohsiung","807","Taiwan","TW",{"type":79,"coordinates":212},[213,214],120.31333,22.61626,{"lat":214,"lon":213},[217],{"name":218,"role":66,"phone":219,"phoneExt":19,"email":220},"Yen-Hsu Chen","+886975356117","infchen@gmail.com",{"facility":222,"status":120,"city":223,"state":223,"zip":224,"country":209,"countryCode":210,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Taichung Veterans General Hospital","Taichung","407",{"type":79,"coordinates":226},[227,228],120.6839,24.1469,{"lat":228,"lon":227},[231],{"name":232,"role":66,"phone":233,"phoneExt":19,"email":234},"Po-Yu Liu","+8860963417010","liupoyu@gmail.com",{"facility":236,"status":120,"city":237,"state":237,"zip":238,"country":209,"countryCode":210,"cosmosGeoPoint":19,"geoPoint":19,"contacts":239},"Taipei Medical University Hospital","Taipei","110",[240],{"name":241,"role":66,"phone":242,"phoneExt":243,"email":244},"Ming-Che Liu","+886227372181","8265","d204097002@tmu.edu.tw",{"facility":246,"status":120,"city":247,"state":247,"zip":248,"country":209,"countryCode":210,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"Taoyuan General Hospital","Taoyuan","33004",{"type":79,"coordinates":250},[251,252],121.29696,24.99368,{"lat":252,"lon":251},[255],{"name":256,"role":66,"phone":257,"phoneExt":258,"email":259},"Chien-Yu Cheng","+88633699721","8311","s841060@gm.ym.edu.tw",{"facility":261,"status":120,"city":247,"state":247,"zip":262,"country":209,"countryCode":210,"cosmosGeoPoint":263,"geoPoint":265,"contacts":266},"Chang Gung Memorial Hospital, Linkou Branch","333",{"type":79,"coordinates":264},[251,252],{"lat":252,"lon":251},[267],{"name":268,"role":66,"phone":269,"phoneExt":19,"email":270},"Ching-Tai Huang","+886975368179","chingtaihuang@gmail.com",{"facility":272,"status":72,"city":273,"state":273,"zip":274,"country":275,"countryCode":276,"cosmosGeoPoint":277,"geoPoint":281,"contacts":282},"Research Institute of Virology","Tashkent","100194","Uzbekistan","UZ",{"type":79,"coordinates":278},[279,280],69.21627,41.26465,{"lat":280,"lon":279},[283],{"name":284,"role":66,"phone":285,"phoneExt":19,"email":286},"Erkin Isakovich Musabayev","+998712248326","drmusabaev1956@gmail.com",{"type":288,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100605014","phase-2-early-stage-trial-to-determine-a-safe-and-effective-dose-for-ratutrelvir-in-patients-with-mild-to-moderate-covid-19-100605014",false,"NCT07157007","Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19","Inclusion Criteria:\n\n1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization.\n2. Initial onset of signs\u002Fsymptoms attributable to COVID-19 within 5 days prior to randomization.\n3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the severity score of 1 or higher according to the following scoring system for the assessment of severity of:\n\nExclusion Criteria:\n\nMedical Conditions:\n\n1. History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19.\n2. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n3. Known medical history of active liver disease .\n4. Receiving dialysis or history of moderate to severe renal impairment.\n5. Compromised immune system.\n6. Acute episode of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease within 30 days before screening.\n7. Suspected or confirmed concurrent active systemic infection..\n\n   Prior\u002FConcomitant Therapy:\n8. Has received or is expected to receive any dose of a SARS-CoV-2 vaccine within 4 months of screening and during the participation in the study.\n9. Concomitant use of any medications or substances that are strong inducers of CYP3A4","ALL","18 Years",{"count":299,"type":300},90,"ESTIMATED","INTERVENTIONAL",[303],"PHASE2","This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.",[306],"COVID - 19","2026-01-17",{"date":309,"type":310},"2026-01-21","ACTUAL",{"date":312,"type":310},"2025-09-16",{"date":314,"type":300},"2026-03",{"name":5,"class":6},15]